Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

CONTEXT: In the Women's Health Initiative estrogen plus progestin trial, after mean (SD) intervention of 5.6 (1.3) years (range 3.7 to 8.6 years) and mean follow-up of 7.9 (1.4) years, breast cancer incidence was increased by combined hormone therapy. However, breast cancer mortality results ha...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA
Hlavní autoři: Chlebowski, Rowan T., Anderson, Garnet L., Gass, Margery, Lane, Dorothy S., Aragaki, Aaron K., Kuller, Lewis H., Manson, JoAnn E., Stefanick, Marcia L., Ockene, Judith, Sarto, Gloria E., MD, Karen C. Johnson, Wactawski-Wende, Jean, Ravdin, Peter M., Schenken, Robert, Hendrix, Susan L., Rajkovic, Aleksandar, Rohan, Thomas E., Yasmeen, Shagufta, Prentice, Ross L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142300/
https://ncbi.nlm.nih.gov/pubmed/20959578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2010.1500
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky